Curium is a global nuclear medicine company with more than a century of experience developing, manufacturing and delivering radiopharmaceuticals. Headquartered in Boston, it operates across more than 70 countries, serving healthcare professionals and patients worldwide. The company focuses exclusively on nuclear medicine, combining diagnostic imaging and therapeutic solutions to support patient care, with a growing emphasis on targeted radiopharmaceutical therapies for cancer.

Its portfolio includes more than 50 products spanning SPECT, PET, medical devices and therapeutics. Curium’s solutions support the diagnosis and management of conditions across oncology, cardiology, neurology, endocrinology, kidney and liver health, and other disease areas. The company also provides radionuclide generator technologies for diagnostic isotope production.

Curium invests in research and development to advance radiodiagnostics and radiotherapeutics, supported by a pipeline, research partnerships and independent research initiatives. Its global infrastructure includes manufacturing sites and radiopharmacies, helping deliver products to healthcare customers. Curium also offers educational resources for healthcare professionals, alongside information and support for patients and caregivers.